Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$106.52 USD

106.52
379,870

-1.99 (-1.83%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $106.51 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

ITGR or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS

by Zacks Equity Research

InspireMD's (NSPR) CE Mark Recertification under MDR is likely to help the company boost the CGuard EPS for carotid artery revascularization care along with advancing with new products.

Zacks Equity Research

Modular Medical (MODD) Pairing Technology Issued New U.S. Patent

by Zacks Equity Research

Modular Medical's (MODD) latest U.S. patent is likely to protect the company's technology addressing pairing and allow clinicians to easily upload and review patients' data.

Zacks Equity Research

CONMED (CNMD) Misses on Q4 Earnings, Beats Revenue Estimates

by Zacks Equity Research

CONMED's (CNMD) adjusted fourth-quarter earnings misses while sales beat estimates on the back of strong growth in the United States and international markets. Gross margin improves with a rise in sales.

Zacks Equity Research

Philips' (PHG) New Innovation to Enhance Cardiovascular Imaging

by Zacks Equity Research

Philips' (PHG) latest X11-4t Mini 3D TEE transducer is likely to have an edge over the traditional 3D TEE in terms of catering to a broader range of patients and improved overall comfort.

Zacks Equity Research

LabCorp (LH) Unveils Test for Preeclampsia in Pregnant Women

by Zacks Equity Research

LabCorp (LH) test System, which is available through clinicians, is the first FDA-cleared biomarker test to aid in the risk assessment of progression to severe preeclampsia.

Zacks Equity Research

Revvity (RVTY) Q4 Earnings Top, EPS View Above Expectation

by Zacks Equity Research

Revvity's (RVTY) fourth-quarter results showcase the decline in segmental revenues. However, the company's earnings and revenues beat their respective estimates.

Zacks Equity Research

Cardinal Health (CAH) Buys Specialty Networks to Boost Workflow

by Zacks Equity Research

Cardinal Health (CAH) acquires Specialty Network to technologically strengthen its specialty therapeutic areas. The acquisition also supports the company's ongoing Navista Network.

Zacks Equity Research

Cardinal Health (CAH) Beats on Q2 Earnings, Ups '24 EPS View

by Zacks Equity Research

Cardinal Health's (CAH) second-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.

Zacks Equity Research

Thermo Fisher (TMO) Q4 Earnings Top Estimates, Gross Margin Down

by Zacks Equity Research

Strength in PPI business contributed to Thermo Fisher's (TMO) fourth-quarter revenue growth.

Zacks Equity Research

BD's (BDX) Tie-Up to Offer AI-Based Digital System for Pap Test

by Zacks Equity Research

BD's (BDX) latest partnership is likely to aid cytotechnologists and pathologists to efficiently identify evidence of cervical cancer and pre-cancerous lesions.

Zacks Equity Research

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX) owing to its strength in the Breast Health and GYN Surgical segments.

Zacks Equity Research

Stryker's (SYK) Q4 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments and geographies. Operating and gross margins increased, with earnings and revenues beating estimates.

Zacks Equity Research

Cencora (COR) Beats on Q1 Earnings & Revenues, Ups 2024 Outlook

by Zacks Equity Research

Cencora's (COR) first-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Zacks Equity Research

Here's Why You Should Retain Neogen (NEOG) Stock for Now

by Zacks Equity Research

Investors are optimistic about Neogen (NEOG) on strong growth in Animal and Food Safety businesses.

Zacks Equity Research

Charles River (CRL) Launches Animal-Free Endotoxin Test

by Zacks Equity Research

Charles River's (CRL) latest launch expands on Charles River's existing Trillium rCR vial product.

Zacks Equity Research

ClearPoint's (CLPT) Neuro Systems to Boost Neurosurgeries

by Zacks Equity Research

ClearPoint (CLPT) is likely to provide effective neurosurgical operations with the installation of the ClearPoint Prism Neuro Laser Therapy System and the Neuro Navigation System.

Zacks Equity Research

Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Zacks Equity Research

Accuray's (ARAY) CyberKnife S7 to Enhance Radiation Treatment

by Zacks Equity Research

Accuray's (ARAY) latest generation CyberKnife S7 System is expected to boost the cancer treatment capabilities of the Providence Swedish Radiosurgery Center.

Zacks Equity Research

Bruker (BRKR) to Advance in Lab Automation With New Buyout

by Zacks Equity Research

This strategic move positions Bruker (BRKR) to further strengthen its Project Accelerate 2.0 initiative, focusing on "Assays, Software, and Aftermarket."

Zacks Equity Research

AngioDynamics' (ANGO) New XL Catheter to Help in PAD Treatment

by Zacks Equity Research

AngioDymics' (ANGO) new FDA-approved Auryon XL Catheter is likely to boost PAD treatment by eliminating access site complications in Atherectomy procedures.

Zacks Equity Research

BD (BDX) Collaborates With Hamilton to Benefit Researchers

by Zacks Equity Research

Becton, Dickinson and Company (BDX) partners with Hamilton to boost its portfolio of single-cell multiomics solutions, enabling researchers to perform more confident experiments.

Zacks Equity Research

Universal Health (UHS) Up 5.3% in 6 Months: More Room to Run?

by Zacks Equity Research

Universal Health's (UHS) rising patient volumes and better pricing position the company well for growth.

Zacks Equity Research

Surmodics' (SRDX) New Device to Boost Its Thrombectomy Platform

by Zacks Equity Research

Surmodics (SRDX) new addition to its Pounce Thrombectomy Platform is recommended for use in vessels with a diameter between 2 mm and 4 mm for clot removal.

Zacks Equity Research

Here's Why Integer (ITGR) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.